Literature DB >> 7726497

Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers.

C Lin1, E Radwanski, M Affrime, M N Cayen.   

Abstract

The pharmacokinetics of ceftibuten, a new cephalosporin antibiotic, and its conversion product, ceftibutentrans, were studied in healthy male volunteers following daily oral administration of a 400-mg capsule for 7 days. Mean concentrations of ceftibuten in plasma obtained on day 5 were similar to those obtained on day 7. Analysis of variance indicated that the concentrations in plasma on days 5 and 7 were at steady state. The mean accumulation factor was 1.14 for day 5 and 1.13 for day 7. The half-life (2.4 h) was independent of the duration of drug administration, and the mean maximum concentration of drug in plasma was 18 to 19 micrograms/ml. Urinary excretion was the major elimination route for ceftibuten, by which 57 to 59% of the drug was excreted unchanged over a 24-h period. The amounts of ceftibuten-trans in plasma and urine were low.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726497      PMCID: PMC162542          DOI: 10.1128/AAC.39.2.356

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.

Authors:  K M Deppermann; H Lode; G Höffken; G Tschink; C Kalz; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

2.  Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects.

Authors:  R A Blouin; J Kneer; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Treatment of acute uncomplicated urinary tract infection with ceftibuten.

Authors:  G E Stein; S Christensen; N Mummaw
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

4.  The pharmacokinetics of cefixime in the fasted and fed state.

Authors:  R D Faulkner; W Bohaychuk; J D Haynes; R E Desjardins; A Yacobi; B M Silber
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

7.  Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.

Authors:  A Bauernfeind
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

8.  Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.

Authors:  A Bauernfeind
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

9.  Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

Authors:  S M Harding; P E Williams; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

10.  Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

View more
  2 in total

1.  Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.

Authors:  James Cohen Stuart; Maurine Leverstein-Van Hall; Willemijn Kortmann; J Verlind; Frouke Mulder; Jelle Scharringa; Ad Fluit; Miquel Ekkelenkamp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-16       Impact factor: 3.267

2.  Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.

Authors:  Cassandra L Chatwin; Jodie C Hamrick; Robert E L Trout; Cullen L Myers; Susan M Cusick; William J Weiss; Mark E Pulse; Luigi Xerri; Christopher J Burns; Gregory Moeck; Denis M Daigle; Kaitlyn John; Tsuyoshi Uehara; Daniel C Pevear
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.